TRUL yields 2000000.00% · ABBV yields 3.12%● Live data
📍 TRUL pulled ahead of the other in Year 1
Combined, TRUL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRUL + ABBV for your $10,000?
Trulite, Inc., a development stage company, engages in the development, production, sourcing, marketing, and sale of portable, semi-portable and stationary products, components, and systems that generate powers for off-grid applications in the United States. The company offers hydrogen fuel cells, photovoltaic solar panels, wind micro-turbines, batteries, charge controllers, and inverters. It provides HydroCell that utilizes a cartridge filled with a chemical hydride that, when injected with water, produces hydrogen on demand for portable and stationary power devices; and integrated fuel cell power generation system that uses the HydroCell. The company also provides Kitty Hawk system, which consists of various technologies that generates hydrogen gas from dry chemical hydride compounds; transforms the hydrogen gas into electricity; and controls for the flow of hydrogen for the actual generation of electricity. Its products are used for back-up power, off-grid power, and remote monitoring applications. The company was founded in 2004 and is based in Houston, Texas.
Full TRUL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.